Esophageal Squamous Cell Carcinoma

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab	FDA
Sensitivity (+)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Ipilimumab, Nivolumab	HC
Sensitivity (+)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Nivolumab	HC
Sensitivity (+)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Nivolumab, Oxaliplatin	HC
Sensitivity (+)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Ipilimumab, Nivolumab	HC